Knezevic et al., 2021b), without the use of a carrier or peptidase inhibitor, for stable gastric pentadecapeptide BPC 157 (10 g or 10 ng/kg subcutaneously), a partial sequence of the human gastric juice protein BPC, which is freely soluble in water at pH 7.0 and in saline
As of March 2026, availability may still vary by state
Individuals with Gastric Issues: Individuals experiencing inflammatory bowel conditions or gastric ulcers utilize the peptide for its mucosal protective properties
one limited ulcerative-colitis meeting abstract What has been observed Protective and healing effects in experimental gastrointestinal injury models What remains unknown Whether it is effective or safe for any human gastrointestinal condition Tendons and ligaments Evidence available Mainly animal studies and reviews What has been observed Changes in healing markers and tissue organisation in experimental injuries What remains unknown Whether it improves pain, function or healing time in people Muscle and bone Evidence available Mainly animal studies What has been observed Experimental findings involving muscle injury and bone repair What remains unknown Human effectiveness, appropriate formulation, long-term safety and meaningful clinical outcomes Wounds and blood-vessel signalling Evidence available Laboratory and animal research What has been observed Proposed effects involving angiogenesis, nitric oxide and fibroblast activity What remains unknown Whether these mechanisms translate into a net human benefit or introduce other risks Pain and urological symptoms Evidence available Very small exploratory human reports What has been observed Preliminary observations in limited groups What remains unknown Reliability, placebo effect, comparative effectiveness and safety General safety Evidence available Small, short human exposures plus animal toxicology What has been observed No clear safety profile can be established from the available data What remains unknown Immune reactions, impurities, interactions, long-term effects and route-specific risks How strong is the human evidence
